{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:50:50Z","timestamp":1792673450689,"version":"4.5.0"},"reference-count":61,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The co-occurrence of human immunodeficiency virus (HIV) and tuberculosis (TB) infection poses a significant global health challenge. Treatment of HIV and TB co-infection often necessitates combination therapy involving antiretroviral therapy (ART) for HIV and anti-TB medications, which introduces the potential for drug\u2013drug interactions (DDIs). These interactions can significantly impact treatment outcomes, the efficacy of treatment, safety, and overall patient well-being. This review aims to provide a comprehensive analysis of the DDIs between anti-HIV and anti-TB drugs as well as potential adverse effects resulting from the concomitant use of these medications. Furthermore, such findings may be used to develop personalized therapeutic strategies, dose adjustments, or alternative drug choices to minimize the risk of adverse outcomes and ensure the effective management of HIV and TB co-infection.<\/jats:p>","DOI":"10.3390\/v16030321","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T04:23:10Z","timestamp":1708489390000},"page":"321","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["HIV\u2013TB Coinfection: Current Therapeutic Approaches and Drug Interactions"],"prefix":"10.3390","volume":"16","author":[{"given":"Inesa","family":"Navasardyan","sequence":"first","affiliation":[{"name":"College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Miwalian","sequence":"additional","affiliation":[{"name":"College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8736-1256","authenticated-orcid":false,"given":"Aelita","family":"Petrosyan","sequence":"additional","affiliation":[{"name":"College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Yeganyan","sequence":"additional","affiliation":[{"name":"College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2586-1160","authenticated-orcid":false,"given":"Vishwanath","family":"Venketaraman","sequence":"additional","affiliation":[{"name":"College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (WHO) (2023, October 28). HIV and AIDS. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"638573","DOI":"10.3389\/fimmu.2021.638573","article-title":"The Importance of Glycans of Viral and Host Proteins in Enveloped Virus Infection","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"German Advisory Committee Blood (Arbeitskreis Blut), Subgroup \u2018Assessment of Pathogens Transmissible by Blood\u2019 (2016). Human Immunodeficiency Virus (HIV). Transfus. Med. Hemother., 43, 203\u2013222.","DOI":"10.1159\/000445852"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1089\/apc.2016.0100","article-title":"Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment","volume":"30","author":"Woodham","year":"2016","journal-title":"AIDS Patient Care STDS"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"a006882","DOI":"10.1101\/cshperspect.a006882","article-title":"HIV-1 reverse transcription","volume":"2","author":"Hu","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3389\/fimmu.2017.00580","article-title":"Pathophysiology of CD4+ T-Cell Depletion in HIV-1 and HIV-2 Infections","volume":"8","author":"Karthigeyan","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Foka, F.E.T., and Mufhandu, H.T. (2023). Current ARTs, Virologic Failure, and Implications for AIDS Management: A Systematic Review. Viruses, 15.","DOI":"10.3390\/v15081732"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.1021\/acs.chemrev.1c00043","article-title":"Chemical Synthesis of Cell Wall Constituents of Mycobacterium tuberculosis","volume":"121","author":"Holzheimer","year":"2021","journal-title":"Chem. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3389\/fimmu.2018.00438","article-title":"Mycobacterium tuberculosis Infection and Innate Responses in a New Model of Lung Alveolar Macrophages","volume":"9","author":"Woo","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Domingo-Gonzalez, R., Prince, O., Cooper, A., and Khader, S.A. (2016). Cytokines and Chemokines in Mycobacterium tuberculosis Infection. Microbiol. Spectr., 4.","DOI":"10.1128\/microbiolspec.TBTB2-0018-2016"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.14745\/ccdr.v43i34a01","article-title":"Latent tuberculosis infection: An overview","volume":"43","author":"Kiazyk","year":"2017","journal-title":"Can. Commun. Dis. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"a017871","DOI":"10.1101\/cshperspect.a017871","article-title":"Tuberculosis and HIV Coinfection","volume":"5","author":"Bruchfeld","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11908-020-00726-x","article-title":"Latent Tuberculosis and HIV Infection","volume":"22","author":"Bares","year":"2020","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3389\/fped.2019.00350","article-title":"Immune Response to Mycobacterium tuberculosis: A Narrative Review","volume":"7","author":"Lodi","year":"2019","journal-title":"Front. Pediatr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"820134","DOI":"10.3389\/fimmu.2022.820134","article-title":"In the Thick of It: Formation of the Tuberculous Granuloma and Its Effects on Host and Therapeutic Responses","volume":"13","author":"Cronan","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.tube.2016.02.010","article-title":"HIV-1 and the Mycobacterium tuberculosis granuloma: A systematic review and meta-analysis","volume":"98","author":"Diedrich","year":"2016","journal-title":"Tuberculosis"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lingappa, J.R., Lingappa, V.R., and Reed, J.C. (2021). Addressing Antiretroviral Drug Resistance with Host-Targeting Drugs-First Steps towards Developing a Host-Targeting HIV-1 Assembly Inhibitor. Viruses, 13.","DOI":"10.3390\/v13030451"},{"key":"ref_18","first-page":"411","article-title":"Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics","volume":"15","author":"Holec","year":"2017","journal-title":"Curr. HIV Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/em.20223","article-title":"A brief overview of mechanisms of mitochondrial toxicity from NRTIs","volume":"48","author":"Kohler","year":"2007","journal-title":"Environ. Mol. Mutagen."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"18567","DOI":"10.7448\/IAS.16.1.18567","article-title":"Non-nucleoside reverse transcriptase inhibitors: A review on pharmacokinetics, pharmacodynamics, safety and tolerability","volume":"16","author":"Usach","year":"2013","journal-title":"J. Int. AIDS Soc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12977-022-00608-1","article-title":"A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection","volume":"19","author":"Zhao","year":"2022","journal-title":"Retrovirology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7084","DOI":"10.1021\/jm050549e","article-title":"Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors","volume":"48","author":"Barreca","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1021\/acsinfecdis.0c00819","article-title":"HIV-1 Integrase Inhibitors with Modifications That Affect Their Potencies against Drug Resistant Integrase Mutants","volume":"7","author":"Smith","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11244","DOI":"10.1073\/pnas.200139397","article-title":"HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase","volume":"97","author":"Espeseth","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/cid\/cit697","article-title":"Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009\u20132012","volume":"58","author":"Hurt","year":"2014","journal-title":"Clin. Infect Dis."},{"key":"ref_26","first-page":"95","article-title":"HIV protease inhibitors: A review of molecular selectivity and toxicity","volume":"7","author":"Lv","year":"2015","journal-title":"HIV AIDS"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"Riddler","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/0253-7184.55471","article-title":"CCR5 inhibitors: Emerging promising HIV therapeutic strategy","volume":"30","author":"Rao","year":"2009","journal-title":"Indian J. Sex. Transm. Dis. AIDS"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.4049\/jimmunol.1501176","article-title":"Transient Surface CCR5 Expression by Naive CD8+ T Cells within Inflamed Lymph Nodes Is Dependent on High Endothelial Venule Interaction and Augments Th Cell-Dependent Memory Response","volume":"196","author":"Askew","year":"2016","journal-title":"J. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Beccari, M.V., Mogle, B.T., Sidman, E.F., Mastro, K.A., Asiago-Reddy, E., and Kufel, W.D. (2019). Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.00110-19"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0b013e3182732746","article-title":"Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope","volume":"62","author":"Pace","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_33","unstructured":"Centers for Disease Control and Prevention (2023, October 30). Treatment for TB Disease, Available online: https:\/\/www.cdc.gov\/tb\/topic\/treatment\/tbdisease.htm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"a017863","DOI":"10.1101\/cshperspect.a017863","article-title":"Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis","volume":"5","author":"Seung","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_35","unstructured":"Beloor Suresh, A., Rosani, A., Patel, P., and Wadhwa, R. (2023). StatPearls [Internet], StatPearls Publishing."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1038\/emi.2014.17","article-title":"The impact of drug resistance on Mycobacterium tuberculosis physiology: What can we learn from rifampicin?","volume":"3","author":"Koch","year":"2014","journal-title":"Emerg. Microbes Infect."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1365-2958.2006.05467.x","article-title":"Mechanisms of action of isoniazid","volume":"62","author":"Timmins","year":"2006","journal-title":"Mol. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2013.11.011","article-title":"Mycolic acids: Structures, biosynthesis, and beyond","volume":"21","author":"Marrakchi","year":"2014","journal-title":"Chem. Biol."},{"key":"ref_39","first-page":"1","article-title":"Mechanisms of Pyrazinamide Action and Resistance","volume":"2","author":"Zhang","year":"2013","journal-title":"Microbiol. Spectr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1128\/AAC.00204-15","article-title":"Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates","volume":"59","author":"Valafar","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/antibiotics3030317","article-title":"Drug Resistance Mechanisms in Mycobacterium tuberculosis","volume":"3","author":"Palomino","year":"2014","journal-title":"Antibiotics"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/WNO.0000000000000141","article-title":"Optochiasmatic and peripheral neuropathy due to ethambutol overtreatment","volume":"34","author":"Geyer","year":"2014","journal-title":"J. Neuroophthalmol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"bcr2013201469","DOI":"10.1136\/bcr-2013-201469","article-title":"Antitubercular drug-induced violent suicide of a hospitalised patient","volume":"2014","author":"Behera","year":"2014","journal-title":"BMJ Case Rep."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Baku\u0142a, Z., Napi\u00f3rkowska, A., Bielecki, J., Augustynowicz-Kope\u0107, E., Zwolska, Z., and Jagielski, T. (2013). Mutations in the embB gene and their association with ethambutol resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates from Poland. Biomed. Res. Int., 2013.","DOI":"10.1155\/2013\/167954"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jgar.2017.09.017","article-title":"Analysis of isoniazid and rifampicin resistance in Mycobacterium tuberculosis isolates in Morocco using GenoType\u00ae MTBDRplus assay","volume":"12","author":"Ennassiri","year":"2018","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_46","unstructured":"Centers for Disease Control and Prevention (2023, October 30). TB Treatment for Persons with HIV, Available online: https:\/\/www.cdc.gov\/tb\/topic\/treatment\/tbhiv.htm."},{"key":"ref_47","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents (2023, October 30). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin: Clinical relevance","volume":"42","author":"Niemi","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003088-200241090-00004","article-title":"Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis","volume":"41","author":"Viciana","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1183\/09031936.00110210","article-title":"Clinical management of tuberculosis and HIV-1 co-infection","volume":"36","author":"Schutz","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.5588\/ijtld.11.0068","article-title":"Experience with rifabutin replacing rifampin in the treatment of tuberculosis","volume":"15","author":"Horne","year":"2011","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s11904-020-00529-8","article-title":"Are We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB","volume":"17","author":"Ignatius","year":"2020","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_54","unstructured":"(2020). WHO Consolidated Guidelines on Tuberculosis: Tuberculosis Preventive Treatment: Module 1: Prevention [Internet], World Health Organization."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.15585\/mmwr.mm7108a1","article-title":"Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis\u2014United States, 2022","volume":"71","author":"Carr","year":"2022","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Azevedo-Pereira, J.M., Pires, D., Calado, M., Mandal, M., Santos-Costa, Q., and Anes, E. (2023). HIV\/Mtb Co-Infection: From the Amplification of Disease Pathogenesis to an \u201cEmerging Syndemic\u201d. Microorganisms, 11.","DOI":"10.3390\/microorganisms11040853"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.antiviral.2017.07.011","article-title":"Dual-targeted anti-TB\/anti-HIV heterodimers","volume":"145","author":"Alexandrova","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Yang, B., Mukherjee, T., Radhakrishnan, R., Paidipally, P., Ansari, D., John, S., Vankayalapati, R., Tripathi, D., and Yi, G. (2023). HIV-Differentiated Metabolite N-Acetyl-L-Alanine Dysregulates Human Natural Killer Cell Responses to Mycobacterium tuberculosis Infection. Int. J. Mol. Sci., 24.","DOI":"10.1101\/2023.02.28.530445"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Herbert, C., Luies, L., Loots, D.T., and Williams, A.A. (2023). The metabolic consequences of HIV\/TB co-infection. BMC Infect. Dis., 23.","DOI":"10.1186\/s12879-023-08505-4"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"742822","DOI":"10.3389\/fimmu.2021.742822","article-title":"Modulation of Cystatin C in Human Macrophages Improves Anti-Mycobacterial Immune Responses to Mycobacterium tuberculosis Infection and Coinfection With HIV","volume":"12","author":"Pires","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"E964","DOI":"10.1073\/pnas.1711853115","article-title":"Complement pathway gene activation and rising circulating immune complexes characterize early disease in HIV-associated tuberculosis","volume":"115","author":"Esmail","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/3\/321\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:02:01Z","timestamp":1760104921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/3\/321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":61,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["v16030321"],"URL":"https:\/\/doi.org\/10.3390\/v16030321","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]}}}